1. India Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Dr. Lalchandani Labs Ltd.

Dr. Lalchandani Labs Ltd.

BBSE:DLCL
7.15
INR
-0.34
(-4.54%)
127.91MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
2.35
3.2
5.08
7.59
4.68
8.82
10.2
16.39
18.9
8.47
8.1
10.25
4.85
- -
Basic EPS, GAAP
0.07
0.54
0.54
1.19
0.44
0.89
0.79
1.69
1.56
-2.63
1.04
0.96
0.07
- -
Free Cash Flow per Basic Share
0.82
0.83
0.03
0.99
0.98
-3.38
-1.19
-1.84
1.52
-0.51
-0.56
0.66
-1.27
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.15
0.67
1.46
1.54
5.59
13.54
14.33
16.03
17.6
14.98
16.01
16.71
16.36
16.36
Tangible Book Value per Share
0.15
0.67
1.46
1.54
5.53
13.33
14.19
15.17
16.86
14.36
15.52
16.3
16.13
16.13
Basic Weighted Avg Shares
6
6
6
6
6
6
6
6
6
6
6
4
9
7
Sales/Revenue/Turnover
14
19
30
45
28
53
61
98
113
50
48
45
42
- -
Operating Margin (%)
16.23
24.64
21.66
21.59
17.41
16.15
15.06
17.81
16.84
-8.74
-1.21
8.06
-11.88
- -
Depreciation Expense
- -
- -
1
2
1
3
4
5
6
7
6
6
6
- -
Net Income, GAAP
- -
3
3
7
3
5
5
10
9
-16
6
4
1
- -
Effective Tax Rate (%)
- -
- -
- -
- -
26
25.79
28.23
26.57
27.48
- -
- -
- -
35.01
- -
Profit Margin (%)
2.95
16.74
10.65
15.65
9.42
10.14
7.77
10.34
8.27
-31.01
12.84
9.37
1.52
- -
Working Capital
3
4
8
13
22
44
57
57
59
57
45
52
94
94
LT Debt
10
7
15
16
13
6
15
26
26
33
3
- -
- -
- -
Total Equity
1
4
9
9
33
81
85
96
105
89
95
100
141
141
Return on Invested Capital (%)
16.29
37.95
29.85
37.78
8.37
8.85
6.25
10.44
9.16
- -
6.94
- -
0.49
- -
Return on Capital (%)
15.48
33.84
26.49
31.51
8.67
8.7
6.11
9.75
9.1
- -
6.92
- -
0.49
- -
Return on Common Equity (%)
57.32
129.48
50.7
79.06
12.34
9.36
5.71
11.18
9.32
-16.1
6.69
4.28
0.53
- -

Capital Structure

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
41
46
21
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
9
Market Capitalization
45
100
128

Working Capital

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
109
112
128
Cash, Cash Equivalents & STI
33
35
41
Accounts Receivable, Net
53
56
61
Inventories
13
12
14
Total Current Liabilities
57
58
34
Payables & Accruals
- -
- -
- -
ST Debt
41
46
21
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
47.6%
9.62%
41.94%
Free Cash Flow
154.99%
-194.54%
-479.67%
Net Income, GAAP
-26.98%
-106.38%
-84.78%
Sales/Revenue/Turnover
11.82%
-11.6%
-6.02%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
48
2025
- -
- -
45
2026
- -
- -
42

Semi-annual Earnings Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.04
2025
- -
- -
0.96
2026
- -
- -
0.07

Semi-annual Dividends Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mohit Lalchandani
Full Time Employees
18
Sector
Health services
Industry
Medical/Nursing services
Address
M-20, Basement New Delhi DE India 110048
IPO Date
May 9, 2018
Website
lalchandanipathlab.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Dr Lalchandani Labs Ltd provides diagnostic and related healthcare testing services in India. The company operates NABL-accredited laboratories offering pathology tests across bio-chemistry, hematology, histopathology, microbiology, electrophoresis, virology, cytology, immunoassay, immuno-histochemistry, molecular pathology, DNA and genetic testing; radiology imaging; doctor consultations; hospital laboratory management; corporate health checkups; and blood bank services. It maintains five self-sufficient labs and 15 collection centers primarily in the Delhi/NCR region, with empanelments including CGHS, DJB, MCD and DDA, and serves retail outlets, hospitals such as Primus Super Specialty Hospital and Nanda Hospital, and corporate clients through home sample collection and e-reporting. Founded in 1986 and headquartered in New Delhi, the company converted from a partnership firm to a public limited entity in 2017 and listed on the BSE in 2018 via an IPO. In recent developments, it held its annual general meeting on September 30, 2025, adopting FY2025 financials, re-appointing its managing director and whole-time director, and authorizing a capital increase to Rs 11 crore; the board also scheduled a meeting for December 9, 2025, to consider financial results, while promoter holding decreased by 3.60% over the last quarter.